Arbutus rises after FDA lifts clinical hold for experimental hepatitis B drug

Arbutus Biopharma

Today 12:56

** Shares of Arbutus Biopharma ABUS.O up 5.2% at $4.39 premarket
** Co says FDA notified that the clinical hold on its experimental drug AB-101 has been removed, allowing additional clinical development in the US
** Arbutus is evaluating next steps for the continued development of AB-101, which is an oral PD-L1 inhibitor is being studied in chronic hepatitis B patients
** Up to last close, stock down 13% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))